---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286125508.md"
description: "Halozyme Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results and reaffirmed its FY2026 adjusted EPS and FY2026 sales guidance. Also, the company announced a new $1 billion share buyback program."
datetime: "2026-05-12T15:11:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286125508.md)
  - [en](https://longbridge.com/en/news/286125508.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286125508.md)
---

# 

Halozyme Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results and reaffirmed its FY2026 adjusted EPS and FY2026 sales guidance. Also, the company announced a new $1 billion share buyback program.

### Related Stocks

- [HALO.US](https://longbridge.com/en/quote/HALO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Halozyme Therapeutics (NASDAQ:HALO) Releases FY 2026 Earnings Guidance](https://longbridge.com/en/news/286000530.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)
- [Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition](https://longbridge.com/en/news/286608288.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)